84 studies found for:    Open Studies | "Conjunctivitis"
Show Display Options
Rank Status Study
21 Recruiting Study for Evaluating Life Quality in Patients With Rhinoconjunctivitis
Condition: Allergic Rhinoconjunctivitis
Intervention:
22 Unknown  Allergic Eye Disease Tear Mediators
Condition: Allergic Eye Disease
Intervention: Drug: olopatadine
23 Recruiting Efficacy and Safety of LAIS® Mites Sublingual Tablets
Condition: Allergic Conditions
Intervention: Drug: LAIS®
24 Recruiting DBPC-trial of Subcutaneous Vitamin D3 Comparing Allergic Patients and Healthy Controls.
Condition: Hypersensitivity
Interventions: Drug: Paricalcitol;   Drug: Placebo (for paricalcitol)
25 Recruiting Sanitation, Water, and Instruction in Face-washing for Trachoma
Condition: Trachoma
Interventions: Behavioral: Water, sanitation, and hygiene (WASH) intervention;   Behavioral: Standard of care WASH intervention;   Drug: Targeted antibiotic treatment;   Drug: Delayed mass antibiotic treatment;   Drug: Mass antibiotic treatment
26 Recruiting Water Uptake for Health in Amhara Pilot
Condition: Trachoma
Intervention: Behavioral: instruction in soap-making and hygiene education
27 Recruiting Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Conditions: Infection;   Hypertension;   Pain;   Reflux;   Edema;   Hyperlipidemia;   Hypotension;   Hypercholesterolemia;   Sedation;   Anxiolysis;   Benzodiazepine Withdrawal;   Bipolar Disorder;   Autistic Disorder;   Schizophrenia;   Influenza Treatment or Prophylaxis;   Acute Decompensated Heart Failure;   Stable Angina;   Life-threatening Fungal Infections;   Nosocomial Pneumonia;   Community Acquired Pneumonia;   Acute Bacterial Exacerbation of Chronic Bronchitis;   Complicated Skin and Skin Structure Infections;   Uncomplicated Skin and Skin Structure Infections;   Chronic Bacterial Prostatitis;   Complicated Urinary Tract Infections;   Acute Pyelonephritis;   Uncomplicated Urinary Tract Infections;   Inhalational Anthrax (Post-Exposure);   Infantile Hemangioma;   Withdrawal;   Inflammation;   Bacterial Septicemia;   Cytomegalovirus Retinitis;   Herpes Simplex Virus;   Adenovirus;   Brain Swelling;   Airway Swelling;   Adrenal Insufficiency;   Anxiety;   Nausea;   Vomiting;   Convulsions;   Muscle Spasms;   Seizures;   Epilepsy;   Bartonellosis;   Brucellosis;   Cholera;   Plague;   Psittacosis;   Q Fever;   Relapsing Fever;   Rocky Mountain Spotted Fever;   Trachoma;   Tularemia;   Typhus Fever;   Bronchospasm;   Cardiac Arrest;   Hypersensitivity Reaction;   Cyanide Poisoning;   Acute Bacterial Sinusitis;   Bacterial Meningitis;   Sepsis;   Gastroparesis;   Opioid Addiction;   Migraines;   Headaches
Intervention: Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
28 Not yet recruiting Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy
Conditions: Rhinitis;   Rhinoconjunctivitis
Interventions: Biological: MM09 Mannosylated 5.000 subcutaneous;   Biological: MM09 Mannosylated 10.000 subcutaneous;   Biological: MM09 Mannosylated 30.000 subcutaneous;   Biological: MM09 Mannosylated 50.000 subcutaneous;   Biological: MM09 Mannosylated 5.000 sublingual;   Biological: MM09 Mannosylated 10.000 sublingual;   Biological: MM09 Mannosylated 30.000 sublingual;   Biological: MM09 Mannosylated 50.000 sublingual;   Biological: Subcutaneous placebo;   Biological: Sublingual placebo
29 Not yet recruiting Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy
Conditions: Rhinitis;   Rhinoconjunctivitis
Interventions: Biological: MG56 Mannosylated 5.000 subcutaneous;   Biological: MG56 Mannosylated 10.000 subcutaneous;   Biological: MG56 Mannosylated 30.000 subcutaneous;   Biological: MG56 Mannosylated 50.000 subcutaneous;   Biological: MG56 Mannosylated 5.000 sublingual;   Biological: MG56 Mannosylated 10.000 sublingual;   Biological: MG56 Mannosylated 30.000 sublingual;   Biological: MG56 Mannosylated 50.000 sublingual;   Biological: Subcutaneous placebo;   Biological: Sublingual placebo
30 Recruiting A Multicenter, Open Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica
Condition: Rhinoconjunctivitis
Intervention: Biological: Allergovac depot with Parietaria judaica pollen extract
31 Recruiting Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma
Conditions: Rhinitis;   Rhinoconjunctivitis;   Asthma
Interventions: Biological: DP/MG/14-1;   Biological: DP/MG/14-2
32 Not yet recruiting Exploring Immune Cell Signatures in Autoimmunity and Dry Eye Syndrome
Conditions: Autoimmunity;   Dry Eye Syndrome
Intervention: Other: Cross-sectional study
33 Not yet recruiting Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
Condition: Dry Eye
Interventions: Drug: Pregabalin;   Drug: Placebo
34 Recruiting Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: cyclosporine;   Drug: vehicle of OTX-101
35 Recruiting A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: 1% Tavilermide Ophthalmic Solution;   Drug: Placebo Ophthalmic Solution
36 Recruiting Evaluation of Factors Affecting the Tear-film Lipid Layer Thickness
Condition: Dry Eye Syndrome
Intervention:
37 Recruiting A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: 1% Tavilermide Ophthalmic Solution;   Drug: Placebo Ophthalmic Solution
38 Recruiting Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD
Condition: Dry Eye Syndromes
Intervention: Device: M22-IPL
39 Recruiting CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
Condition: Dry Eye Syndromes
Interventions: Drug: Cyclosporine A;   Drug: Placebo
40 Recruiting Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome
Condition: Dry Eye Syndrome
Interventions: Device: T2762;   Device: Optive

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years